BioMarin Pharmaceutical Inc. (LON:0HNC)
53.91
+0.90 (1.70%)
At close: Sep 16, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $825.41M USD in the quarter ending June 30, 2025, with 15.92% growth. This brings the company's revenue in the last twelve months to $3.06B, up 18.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.06B
Revenue Growth
+18.36%
P/S Ratio
3.42
Revenue / Employee
$1.01M
Employees
3,040
Market Cap
7.64B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
BioMarin Pharmaceutical News
- 8 days ago - BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 9 days ago - PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga
- 9 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for ... - GuruFocus
- 10 days ago - BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - PRNewsWire
- 10 days ago - BioMarin Pharmaceutical (BMRN) Sees New Coverage with Neutral Rating | BMRN Stock News - GuruFocus
- 10 days ago - BioMarin (BMRN) Releases Promising PALYNZIQ Study Results for PKU Treatment - GuruFocus
- 11 days ago - BioMarin Pharmaceutical Inc (BMRN) Reveals Promising Phase 3 PEGASUS Study Results for PALYNZIQ ... - GuruFocus